Ross Mitchell named artificial intelligence officer at Moffitt

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Ross Mitchell has joined Moffitt Cancer Center as the artificial intelligence officer.

In this new role, he will lead the cancer center’s efforts to develop digital tools and technologies that utilize computer science to improve the efficiency and quality of cancer care.

Mitchell is also a senior member of Moffitt’s Department of Biostatistics and Bioinformatics and will collaborate with fellow research faculty to optimize projects utilizing artificial intelligence applications.

“Data science is a growing area in cancer research and care. Through the analysis of data, we can better predict outcomes to assist with informed decision-making. Mitchell will help Moffitt identify those business and clinical opportunities where predictive analytics, machine learning and other advanced technologies can be used to improve our patient experience,” said Dana Rollison, vice president, chief data officer and associate center director of Data Science at Moffitt. “He will also bring this skillset to our research enterprise.”

Mitchell comes to Moffitt from the Mayo Clinic in Scottsdale, where he led multiple medical imaging informatics initiatives such as the application of machine learning in brain tumor imaging.

Table of Contents

YOU MAY BE INTERESTED IN

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.
In back-to-back congressional hearings earlier this week, HHS Secretary Robert F. Kennedy Jr. said that the massive staff and budget cuts over which he has presided during his nearly four months on the job as well as even bigger cuts still looming on the horizon are a part of a single plan.
Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login